Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and BTB domain-containing protein 5 (ZBTB5) is a nuclear transcription factor belonging to the BTB/POZ domain protein family, characterized by a POZ/BTB domain at the N-terminus and two C-terminal zinc finger motifs[3][6]. ZBTB5 represses transcription of key genes in the cell cycle, such as p21 and HDM2, by binding to promoter elements and recruiting histone deacetylase complexes via its POZ domain, leading to chromatin remodeling. It is expressed in most tissues, showing elevated levels in certain cancers and is predominantly localized to nuclear speckles[3][6]. ZBTB5 directly modulates cell cycle progression and cell proliferation, and functions as a potential proto-oncogene, partly due to its role in repressing the p53 pathway. Dysfunction or deregulation of ZBTB5 may contribute to tumorigenesis and the development of malignancies by dysregulating cell cycle checkpoints.
No clinically validated mechanism of action for drugs against ZBTB5. Experimental mechanisms referenced include inhibition of transcriptional repression or interruption of its interaction with co-repressor complexes[3][6], but no clinical drugs pursue this.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and BTB domain-containing protein 5 (ZBTB5).